Phentolamine Mesylate Patent Expiration
Phentolamine Mesylate is Used for reversal of soft-tissue anesthesia following intraoral local anesthetic injection. It was first introduced by Novartis Pharmaceuticals Corp
Phentolamine Mesylate Patents
Given below is the list of patents protecting Phentolamine Mesylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Oraverse | US6764678 | Local anesthetic methods and kits |
May 11, 2021
(Expired) | Septodont Holding |
| Oraverse | US6872390 | Local anesthetic methods and kits |
May 11, 2021
(Expired) | Septodont Holding |
| Oraverse | US7229630 | Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof |
Jun 20, 2023
(Expired) | Septodont Holding |
| Oraverse | US7569230 | Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof |
Oct 17, 2023
(Expired) | Septodont Holding |
| Oraverse | US7575757 | Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof | Apr 21, 2025 | Septodont Holding |
| Ryzumvi | US10278918 | Aqueous ophthalmic solutions of phentolamine and medical uses thereof | Jan 31, 2034 | Famygen Life Sci |
| Ryzumvi | US10772829 | Aqueous ophthalmic solutions of phentolamine and medical uses thereof | Jan 31, 2034 | Famygen Life Sci |
| Ryzumvi | US11090261 | Aqueous ophthalmic solutions of phentolamine and medical uses thereof | Jan 31, 2034 | Famygen Life Sci |
| Ryzumvi | US11400077 | Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders | Oct 25, 2039 | Famygen Life Sci |
| Ryzumvi | US11844858 | Aqueous ophthalmic solutions of phentolamine and medical uses thereof | Jan 31, 2034 | Famygen Life Sci |
| Ryzumvi | US9795560 | Aqueous ophthalmic solutions of phentolamine and medical uses thereof | Jan 31, 2034 | Famygen Life Sci |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Phentolamine Mesylate's patents.
Latest Legal Activities on Phentolamine Mesylate's Patents
Given below is the list recent legal activities going on the following patents of Phentolamine Mesylate.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 15 Mar, 2024 | US10772829 |
| Electronic Review | 02 Feb, 2024 | US11844858 |
| Email Notification | 20 Dec, 2023 | US11844858 |
| Recordation of Patent Grant Mailed | 19 Dec, 2023 | US11844858 |
| Patent Issue Date Used in PTA Calculation | 19 Dec, 2023 | US11844858 |
| Recordation of Patent eGrant | 19 Dec, 2023 | US11844858 |
| Mail Patent eGrant Notification | 19 Dec, 2023 | US11844858 |
| Patent eGrant Notification | 19 Dec, 2023 | US11844858 |
| Email Notification | 30 Nov, 2023 | US11844858 |
| Issue Notification Mailed | 29 Nov, 2023 | US11844858 |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Phentolamine Mesylate Generics
Several generic applications have been filed for Phentolamine Mesylate. The first generic version for Phentolamine Mesylate was by Hikma Pharmaceuticals Usa Inc and was approved on Mar 11, 1998. And the latest generic version is by Precision Dose Inc and was approved on Jul 14, 2017.
Given below is the list of companies who have filed for Phentolamine Mesylate generic.
1. PRECISION DOSE INC
Precision Dose Inc has filed for 1 generic for Phentolamine Mesylate. Given below are the details of the strengths of this generic introduced by Precision Dose Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5MG/VIAL | injectable | Prescription | INJECTION | AP | Jul 14, 2017 |
2. HIKMA
Hikma Pharmaceuticals Usa Inc has filed for 1 generic for Phentolamine Mesylate. Given below are the details of the strengths of this generic introduced by Hikma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5MG/VIAL
(reference standard) | injectable | Prescription | INJECTION | AP | Mar 11, 1998 |